Regulation of chromogranin B/secretogranin I and secretogranin II storage in GH4C1 cells.
GH4C1 cells are a rat pituitary tumor cell strain in which the level of cellular prolactin (PRL) and PRL-containing secretory granules can be regulated by hormone treatment. The chromogranins/secretogranins (Sg) are a family of secretory proteins which are widely distributed in the secretory granules of endocrine and neuronal cells. In the present study, we investigated in GH4C1 cell cultures the regulation of the cell content of the Sg by immunoblotting and the relationship between the storage of Sg I and Sg II and PRL by double immunocytochemistry. GH4C1 cells grown in the presence of gelded horse serum, a condition in which these cells contain a low level of secretory granules, contained low levels of PRL, Sg I, and Sg II. Treatment of GH4C1 cells with a combination of 17 beta-estradiol, insulin, and epidermal growth factor for 3 days, known to induce a marked increase in the number of secretory granules, increased the cell contents of PRL, Sg I, and Sg II. To determine whether the induction of PRL was morphologically associated with that of the Sg, the distribution of PRL and the Sg was determined by double immunofluorescence microscopy. After hormone treatment, 54% of cells showed positive PRL immunoreactivity, fluorescence being extranuclear and consistent with staining of the Golgi zone and secretory granules. Forty-six percent of PRL-positive cells stained coincidently for Sg I, while 72% of the PRL cells were also reactive with anti-Sg II. To determine whether PRL storage was associated with storage of at least one of the Sg, cells were stained with anti-PRL and anti-Sg I and anti-Sg II together. Eighty-six percent of PRL cells stained for one or the other of the Sg. Therefore, PRL storage in GH4C1 cell cultures is closely but not completely associated with the storage of Sg I and/or II.
Scammell
J G
JG
Department of Pharmacology, University of South Alabama, College of Medicine, Mobile 36688.
Rosa
P
P
Hille
A
A
Huttner
W B
WB
D000818:Animals; D053378:Chromogranin B; D002864:Chromogranins / Q000378:metabolism*; D003594:Cytoplasmic Granules / Q000187:drug effects / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D007150:Immunohistochemistry / Q000379:methods; D007328:Insulin / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000473:pathology*; D011388:Prolactin / Q000378:metabolism; D011506:Proteins / Q000378:metabolism*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D053378:Chromogranin B; D002864:Chromogranins; D007328:Insulin; D009419:Nerve Tissue Proteins; D011506:Proteins; C506140:chromogranin B, rat; D004958:Estradiol; D004815:Epidermal Growth Factor; D011388:Prolactin